| Current Medical Articles |
|---|
 |
The Motley Fool
March 10, 2010
Brian Orelli |
Up 160% With Room to Run You've got to love biotech and InterMune.   |
The Motley Fool
March 10, 2010
Brian Orelli |
You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't. |
The Motley Fool
March 10, 2010
Jennifer Schonberger |
A Key Representative Weighs In on Financial Reform and Health Care Paul Kanjorski, D-Pa, talks about what needs to change and what needs to get done on Capitol Hill. |
The Motley Fool
March 9, 2010
Brian Orelli |
Are Billions of Dollars in Revenue at Risk? Vaccine makers' lawsuit protection is called into question. |
The Motley Fool
March 9, 2010
Brian Orelli |
The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections. |
The Motley Fool
March 8, 2010
Brian Orelli |
Pfizer Still Dealing With Antitrust Issues The pharma giant sells off some more animal health assets. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
March 5, 2010
Brian Orelli |
How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot. |
BusinessWeek
March 4, 2010
Amanda Bennett |
Lessons of a $618,616 Death Two years after her husband's death, the author's cover story examines the costs of keeping one man alive to fight in the face of a dismal prognosis. |
The Motley Fool
March 4, 2010
Brian Orelli |
Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
March 3, 2010
Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. |
The Motley Fool
March 3, 2010
Brian Orelli |
Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration. |
The Motley Fool
March 2, 2010
Brian Orelli |
Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off. |
Inc.
March 1, 2010
Kasey Wehrum |
The Business of Mission County Hospital A look at the companies that supply the California hospital with virtual records, equipment repair, and laundry services |
InternetNews
March 1, 2010 |
Major Tech Firms Back Online Health Care Cisco, Dell, Google, IBM and Microsoft all make news at the major health care show. |
Chemistry World
February 26, 2010
Sarah Houlton |
Report hits out at GSK's Avandia GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) has been dealt another blow, with the publication of a report by two US senators claiming the company knew about safety problems long before they reached the public domain. |
The Motley Fool
February 26, 2010
Brian Orelli |
Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
February 26, 2010
Brian Orelli |
Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market. |
The Motley Fool
February 26, 2010
Brian Orelli |
Political Theater: More Entertaining Than Helpful Health-care reform, like health-care stocks, remains still stuck in limbo. |
The Motley Fool
February 26, 2010
Tim Hanson |
This Stock Costs Less Than a Sandwich And that makes it a pretty good deal. Female Health Co., a maker of female condoms is still on the AMEX and trading for less than $3 per share. |
BusinessWeek
February 25, 2010
Weintraub & Tirrell |
Eli Lilly's Drug Assembly Line Faced with expiring patents that could weaken sales, Lilly is reorganizing for speed. |
The Motley Fool
February 25, 2010
Brian Orelli |
Transplanting Future Revenue Bristol-Myers Squibb waits for experts to decide the fate of its kidney cancer drug. |
The Motley Fool
February 25, 2010
Brian Orelli |
13 Is Pfizer's Lucky Number Inherited from Wyeth, Prevnar 13 could be a goldmine for Pfizer. |
The Motley Fool
February 25, 2010
Brian Orelli |
An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies. |
The Motley Fool
February 24, 2010
Brian Orelli |
A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year. |
The Motley Fool
February 24, 2010
Brian Orelli |
Medtronic Needs to Regrow a Spine Everything else looks fairly good, but the problem I see involves the slight decline in Medtronic's second-largest segment, spinal products. |
The Motley Fool
February 23, 2010
Brian Orelli |
The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston. |
The Motley Fool
February 23, 2010
Brian Orelli |
Triple-Teaming Cancer for Fun and Profit Pfizer, Merck and Eli Lilly set up a nonprofit, but there may be an ulterior motive. |
The Motley Fool
February 23, 2010
Brian Orelli |
The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu. |
The Motley Fool
February 23, 2010
Brian Orelli |
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. |
The Motley Fool
February 22, 2010
Brian Orelli |
A Huge Business Wrapped Up in Tiny Packages Drug investors shouldn't forget about over-the-counter products. |
The Motley Fool
February 22, 2010
Brian Orelli |
Warning: Avandia Could Cause Drool Among Trial Lawyers An unintended side effect of Glaxo's Avandia might be excessive salivation among trial lawyers. A 342-page report by the Senate Finance Committee is painting the diabetes drug in a not-so-great light. |
The Motley Fool
February 22, 2010
Brian Orelli |
So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits. |
Chemistry World
February 18, 2010
Matt Wilkinson |
Merck joins the cost-cutting crowd Following its merger with Schering-Plough, US drug giant Merck & Co. has announced a 'merger restructuring plan' that in its first phase will see 17,500 jobs cut. |
Chemistry World
February 4, 2010
Matt Wilkinson |
More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets. |
CRM
February 2010
Lauren McKay |
The New-Age Home Aided by SiteSpect, a specialist in elder-care placement boosts Web conversions and better addresses client needs. |
Chemistry World
January 28, 2010
Nina Notman |
AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost. |
Philanthropy
January 1, 2010
Adam Keiper |
Breakthrough Medical research is dominated by government and corporate funding. How can philanthropic dollars find a distinctive niche? |
| There are 6379 old articles available for this category. |
